Ovarian cancer and hormone replacement therapy in the Million Women Study

By V. Beral. 2007

851 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/b298b4be60ff1ee001cf02071a87ee2b9f82ce1d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. D. R. Cox
2. Ie-Ming Shih
3. Amy Berrington de González
4. R. Kurman

In Genetics

1. humAn cArcinogens
2. Iarc Monographs
3. D. R. Cox
4. Ie-Ming Shih
5. Amy Berrington de González
6. peRsonAl hAbIts
7. R. Kurman

In Reproductive Medicine

1. R. Kurman
2. Ie-Ming Shih
3. D. R. Cox
4. Amy Berrington de González
5. E. Lengyel
6. J. Prat

Citations in the corpus

• iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns (2012, background): “, 2006), in the other four (of incident cases), after 5 years of use (Lacey et al., 2002; Folsom et al., 2004; Beral et al., 2007; Danforth et al., 2007).”
• Interpretation of interaction: A review (2007, methodology): “ative interaction (effect reversal) between two primary factors: use of cyclic-combined hormone-replacement therapy (HRT) and body mass index, with respect to the riskof developing endometrial cancer [Beral et al. (2005)]. Women who were of normal body weight (body mass index <25 kg/m2) had a sign”
• Molecular Pathogenesis and Extraovarian Origin of Epithelial Ovarian Cancer. Shifting the Paradigm (2011, positive): “This is consistent with epidemiologic evidence linking decreased ovulation (either as a result of oral contraceptive usage or multiple pregnancies) with a decreased risk of ovarian cancer (73,74).”